Kamel Mhameed

First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel

S. Billan, A. Popovtzer, I. Doweck, 2023, Frontiers in Oncology.

PD1 ligand functionality a biomarker of response to anti PD1 treatment in patients with HNSCC

S. Billan, M. Elkabets, Kamel Mhameed, 2024, NPJ precision oncology.